Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

QWO

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES

Standard Dose
1.84MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview QWO is listed in Drugs@FDA under application 761146 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES Form and strength SOLUTION;SUBCUTANEOUS - 1.84MG/VIAL Sponsor ENDO GLOBAL AESTHETICS LTD Submission history Latest submission status date: 2020-07-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview QWO is listed in Drugs@FDA under application 761146 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES Form and strength SOLUTION;SUBCUTANEOUS - 1.84MG/VIAL Sponsor ENDO GLOBAL AESTHETICS LTD Submission history Latest submission status date: 2020-07-06 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.